Linked Life Data

16729930

Source:http://linkedlifedata.com/resource/pubmed/id/16729930

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
18
pubmed:dateCreated
2006-5-29
pubmed:abstractText
In the IDEAL trial, almost 9,000 patients with coronary heart disease were treated, after randomisation, with atorvastatin, 80 mg daily, or simvastatin, 20 or 40 mg daily, for 4.8 years. The LDL cholesterol level was 0.6 mmol/l lower in the atorvastatin group, a smaller difference than expected, and the 11% reduction in the primary end point (myocardial infarction, cardiac arrest, coronary death) in this group was not statistically significant (p = 0.07). In contrast, several secondary end points, one of which was the primary end point plus stroke, occurred statistically significantly less often in the atorvastatin group.
pubmed:commentsCorrections
pubmed:language
dan
pubmed:journal
pubmed:status
PubMed-not-MEDLINE
pubmed:month
May
pubmed:issn
1603-6824
pubmed:author
pubmed:issnType
Electronic
pubmed:day
1
pubmed:volume
168
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1769-71
pubmed:dateRevised
2006-11-15
pubmed:year
2006
pubmed:articleTitle
[High-dose atorvastatin or normal-dose simvastatin in treatment of patients with coronary heart disease (IDEAL trial)--secondary publication].
pubmed:affiliation
Arhus Universitetshospital, Arhus Sygehus, Medicinsk-kardiologisk Afdeling A. ferryman@mail.tele.dk
pubmed:publicationType
Journal Article, English Abstract